Who We Are
“We hold ourselves to the highest ethical standards and work hard every day to change the face of cancer and diabetes treatment to best serve our patients and the medical community.”
In 2010, OSI Pharmaceuticals, Inc. (OSI) became a wholly owned subsidiary of Astellas US Holding, Inc. which is part of the Astellas US group of companies (Astellas).
OSI is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity. OSI manufactures and sells Tarceva® (erlotinib), a leading cancer medication, and has several prospective new oncology medications in its R&D pipeline. The acquisition of OSI is expected to augment Astellas' strong existing franchises in urology and transplantation, expanding the product portfolio and pipeline of the combined company.
Please visit http://www.us.astellas.com for information on Astellas.
Our Flagship Product
Tarceva (erlotinib) is a small molecule human epidermal growth factor type 1/epidermal growth factor receptor (HER1/EGFR) inhibitor which is currently marketed for the treatment of non-small cell lung cancer and pancreatic cancer.
Products and Pipeline
A key to our long-term success resides in our ability to continue to fund our innovative and differentiated pipeline, both to enhance the Tarceva franchise and seed high-quality research programs in oncology, diabetes and obesity.
Learn more about our pipeline